WMIC: Caliper bolsters product line

Caliper Life Sciences has introduced a series of XenoLight Rediject reagents for in vivo imaging systems at the 2009 World Molecular Imaging Congress (WMIC) in Montreal this week.

Rediject D-Luciferin Ultra is the latest in an expanding range of XenoLight reagents, according to the Hopkinton, Mass.-based firm. It is supplied in a ready-to-inject format, pre-formulated with a tracking agent in order to monitor injection quality and minimize data variability.

Using this reagent in an in vivo imaging system, researchers can validate their techniques and generate more reproducible data in less time, according to Caliper.

In the past year, the company has also introduced two imaging platforms, including the IVIS Kinetic, which uses video-rate imaging to image biological processes in real-time, and the IVIS Lumina XR, Caliper's first instrument to integrate fluorescence, bioluminescence and x-ray capabilities into a single system.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.